Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection

J Clin Oncol. 2011 Aug 10;29(23):e680-1. doi: 10.1200/JCO.2011.35.5651. Epub 2011 Jun 20.

Authors

Maria Chiara Tronconi¹, Francesco Sclafani, Lorenza Rimassa, Carlo Carnaghi, Nicola Personeni, Armando Santoro

Affiliation

¹ Humanitas Cancer Center, Istituto Clinico Humanitas, Istituto Di Ricovero e Cura a Carattere Scientifico, Rozzano, Italy.

PMID: 21690469
DOI: 10.1200/JCO.2011.35.5651

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Cetuximab
Colonic Neoplasms / drug therapy*
Colonic Neoplasms / genetics
Fatal Outcome
Genotype
Humans
Infusions, Intravenous
Irinotecan
Male
Middle Aged
Patient Selection
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins p21(ras)
Risk Factors
ras Proteins / genetics

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins
Irinotecan
Proto-Oncogene Proteins p21(ras)
ras Proteins
Cetuximab
Camptothecin